首页> 美国卫生研究院文献>Journal of Aerosol Medicine and Pulmonary Drug Delivery >Effect of Unintentional Storage and Handling Errors of Inhaled Medications: What Does This Mean for Therapeutic Equivalence Considerations?
【2h】

Effect of Unintentional Storage and Handling Errors of Inhaled Medications: What Does This Mean for Therapeutic Equivalence Considerations?

机译:吸入性药物的非故意存储和处理错误的影响:对于治疗等效性考虑这意味着什么?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Currently, the equivalence and the substitutability of two inhaled medications are mainly driven by comparability of doses, in vitro performance, therapeutic equivalence and sameness, and handling of the inhalers. The packaging configuration is usually not considered as a factor.>Methods: Two capsule-based inhaled tiotropium-containing products that differ by their primary packaging configurations (blister versus bottle) were compared in terms of potential handling and resulting storage errors due to unintentional misuse. Use error scenarios were identified and investigated for both the blister-packaged tiotropium and the bottled tiotropium capsules. The impact of the air exposure resulting from the packaging interaction errors was evaluated in vitro using fine particle dose (FPD) and delivered dose.>Results: Numbers of potential errors and criticality in terms of the potential effect impact on the FPD were larger for the bottled product (between 40% and 90% loss on FPD related to initial dose). The loss of FPD could significantly impact the amount of medication that can actually reach the patient's lungs.>Conclusion: When considering prescribing an inhaled medication, the specifics of the packaging and the patient's abilities and situation shall be taken into account to minimize possible handling and subsequent dosing errors.
机译:>背景:目前,两种吸入药物的等效性和可替代性主要由剂量的可比性,体外性能,治疗等效性和相同性以及吸入器的操作性决定。通常不将包装配置视为因素。>方法:比较了两种基于胶囊的吸入性噻托溴铵产品,这些产品的主要包装配置(泡罩包装与瓶装)有所不同,涉及的潜在处理方式和结果由于意外滥用而导致的存储错误。对于泡罩包装的噻托溴铵和瓶装噻托溴铵胶囊,确定并调查了使用错误情况。使用细颗粒剂量(FPD)和输送剂量在体外评估了包装相互作用误差对空气暴露的影响。>结果:就潜在影响和潜在危害而言,潜在错误和危害的数量瓶装产品的FPD较大(与初始剂量相关的FPD损失40%至90%)。 FPD的损失可能会严重影响实际可以到达患者肺部的药物数量。>结论:在考虑开具吸入药物的处方时,应考虑包装的详细信息以及患者的能力和情况帐户以最大程度地减少可能的处理和后续加料错误。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号